Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases.

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2024-07-01 Epub Date: 2024-05-09 DOI:10.1080/13543784.2024.2351513

Nadia Martinez Naya, Jazmin Kelly, Austin Hogwood, Antonio Abbate, Stefano Toldo

{"title":"Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases.","authors":"Nadia Martinez Naya, Jazmin Kelly, Austin Hogwood, Antonio Abbate, Stefano Toldo","doi":"10.1080/13543784.2024.2351513","DOIUrl":null,"url":null,"abstract":"Introduction: Cannabidiol (CBD) is the primary non-psychoactive chemical derived from Cannabis Sativa, and its growing popularity is due to its potential therapeutic properties while avoiding the psychotropic effects of other phytocannabinoids, such as tetrahydrocannabinol (THC). Numerous pre-clinical studies in cellular and animal models and human clinical trials have demonstrated a positive impact of CBD on physiological and pathological processes. Recently, the FDA approved its use for the treatment of seizures, and clinical trials to test the efficacy of CBD in myocarditis and pericarditis are ongoing.Areas covered: We herein reviewed the current literature on the reported effects of CBD in the cardiovascular system, highlighting the physiological effects and the outcomes of using CBD as a therapeutic tool in pathological conditions to address this significant global health concern.Expert opinion: The comprehensive examination of the literature emphasizes the potential of CBD as a therapeutic option for treating cardiovascular diseases through its anti-inflammatory, vasodilatory, anti-fibrotic, and antioxidant properties in different conditions such as diabetic cardiomyopathy, myocarditis, doxorubicin-induced cardiotoxicity, and ischemia-reperfusion injury.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"699-712"},"PeriodicalIF":4.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2024.2351513","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cannabidiol (CBD) is the primary non-psychoactive chemical derived from Cannabis Sativa, and its growing popularity is due to its potential therapeutic properties while avoiding the psychotropic effects of other phytocannabinoids, such as tetrahydrocannabinol (THC). Numerous pre-clinical studies in cellular and animal models and human clinical trials have demonstrated a positive impact of CBD on physiological and pathological processes. Recently, the FDA approved its use for the treatment of seizures, and clinical trials to test the efficacy of CBD in myocarditis and pericarditis are ongoing.

Areas covered: We herein reviewed the current literature on the reported effects of CBD in the cardiovascular system, highlighting the physiological effects and the outcomes of using CBD as a therapeutic tool in pathological conditions to address this significant global health concern.

Expert opinion: The comprehensive examination of the literature emphasizes the potential of CBD as a therapeutic option for treating cardiovascular diseases through its anti-inflammatory, vasodilatory, anti-fibrotic, and antioxidant properties in different conditions such as diabetic cardiomyopathy, myocarditis, doxorubicin-induced cardiotoxicity, and ischemia-reperfusion injury.

查看原文本刊更多论文

大麻二酚（CBD）在治疗心血管疾病方面的治疗潜力。

简介：大麻二酚（CBD）是从大麻（Cannabis Sativa）中提炼出来的主要非精神活性化学物质，它之所以越来越受欢迎，是因为它具有潜在的治疗特性，同时避免了四氢大麻酚（THC）等其他植物大麻素的精神作用。在细胞和动物模型中进行的大量临床前研究以及人体临床试验都证明了 CBD 对生理和病理过程的积极影响。最近，美国食品和药物管理局批准将 CBD 用于治疗癫痫发作，测试 CBD 对心肌炎和心包炎疗效的临床试验正在进行中：在此，我们回顾了目前有关 CBD 对心血管系统影响的文献报道，强调了 CBD 作为病理条件下治疗工具的生理效应和结果，以解决这一重大的全球健康问题：对文献的全面研究强调了CBD作为治疗心血管疾病的一种选择的潜力，它在糖尿病心肌病、心肌炎、多柔比星诱导的心脏毒性和缺血再灌注损伤等不同病症中具有抗炎、扩张血管、抗纤维化和抗氧化的特性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.